Introduction: Human papillomavirus (HPV) is the leading cause of cervical cancer and genital lesions in women and men, representing an important global health problem. There are still few data about the prevalence and HPV co-infection in Brazilian patients. Objective: This study aims to describe type specific distribution and co-infection of HPV in patients of a private health clinic using HPV DNA testing. Material and Methods: From April 2010 to October 2011, 15,307 consecutive patients of a private health institution in Sao Paulo, Brazil, were tested using a DNA-array assay, which detects simultaneously 24 HPV types - 19 high risk (HR) and 5 low risk (LR) types (PapilloCheck®). Results: HPV infection was detected in 39% of 13,770 female and 65% of 1,537 male samples. The most common HR-HPV types in women were HPV16, 51, 53, 68, 56 (7.3; 7.2; 7.1; 7.1 and 6.7%) followed by types 39, 66, 52, 31 and 58 (4.7 to 3.9%), which accounted for approximately 56.2% of all detected HPV types. LR-HPV 42 (8.5%) and 44/45 (8.2%) were the most frequent LR types. In males, HR-HPV 16, 51, 56, 68, 53, 39 and 66 (7.8; 7.3; 5.3; 4.6; 4.4 and 4.2%) accounted for 38,7% of all types; HPV 6 (12,8%) and 42 (8%) were the most frequent LR types. HPV 18 accounted for only 1,8% and 2,3% of HPV DNA-positive women and men. Co-infection was observed in 16.3% of female and 36.4% of male samples. 7.1% of women and 22.8% of men showed co-infection with three or more types of HPV. Overall, 59.8% of women and 44% of men had only HR type-infections. 17,6% of women and 23,7% of men had only LR-HPV infections. Co-infection with HR and LR-HPV was observed in 22,6% of female and 32,3% of male samples. Conclusion: Our findings show a high HPV infection prevalence and a high proportion of co-infections in our population. These data can be useful to plan in a more efficient way screening programs and application of prophylactic HPV vaccines in Brazil.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5506. doi:1538-7445.AM2012-5506